Skip to main content

Advertisement

SpringerLink
Log in

HBV life cycle and novel drug targets

  • Review Article
  • Published:
Hepatology International Aims and scope Submit manuscript

Abstract

With up to 400 million affected people worldwide, chronic hepatitis B virus (HBV) infection is still a major health care problem. During the last decade, several novel therapeutic approaches have been developed and evaluated. In most regions of the world, interferon-α, and nucleos(t)ide analogues (NUCs) are currently approved. Despite major improvements, none of the existing therapies is optimal since viral clearance is rarely achieved. Recently, a better understanding of the HBV life cycle and the development of novel model systems of HBV infection have led to the development of novel antiviral strategies and drug targets. This review will focus on current and potential future drug targets in the HBV life cycle and strategies to modulate the virus–host interaction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359(14):1486–500

    Article  PubMed  CAS  Google Scholar 

  2. Thimme R, Blum HE. (Therapy of hepatitis B). Praxis (Bern 1994) 2006;95(36):1383–1388

    Google Scholar 

  3. ZF SeegerC, Mason WS. Hepadnaviruses. 5th ed.  Philadelphia: Lippincott, Williams and Wilkins; 2007

    Google Scholar 

  4. Stein LL, Loomba R. Drug targets in hepatitis B virus infection. Infect Disord Drug Targets 2009;9(2):105–116

    PubMed  CAS  Google Scholar 

  5. Urban S, Schulze A, Dandri M, Petersen J. The replication cycle of hepatitis B virus. J Hepatol 2010;52(2):282–284

    Article  PubMed  Google Scholar 

  6. Nassal M. Hepatitis B viruses: reverse transcription a different way. Virus Res 2008;134(1–2):235–249

    Article  PubMed  CAS  Google Scholar 

  7. Balsano C, Alisi A. Viral hepatitis B: established and emerging therapies. Curr Med Chem 2008;15(9):930–939

    Article  PubMed  CAS  Google Scholar 

  8. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50(2):227–242

    Article  Google Scholar 

  9. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351(15):1521–1531

    Article  PubMed  CAS  Google Scholar 

  10. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009;51(3):581–592

    Article  PubMed  CAS  Google Scholar 

  11. Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008;89(Pt 1):1–47

    Article  PubMed  CAS  Google Scholar 

  12. Ank N, West H, Paludan SR. IFN-lambda: novel antiviral cytokines. J Interferon Cytokine Res 2006;26(6):373–379

    Article  PubMed  CAS  Google Scholar 

  13. Stegmann KA, Bjorkstrom NK, Veber H, Ciesek S, Riese P, Wiegand J, Hadem J, Suneetha PV, Jaroszewicz J, Wang C, Schlaphoff V, Fytili P, Cornberg M, Manns MP, Geffers R, Pietschmann T, Guzman CA, Ljunggren HG, Wedemeyer H. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 2010;138(5):1885–1897

    Article  PubMed  CAS  Google Scholar 

  14. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998;67:227–264

    Article  PubMed  CAS  Google Scholar 

  15. Dusheiko G, Antonakopoulos N. Current treatment of hepatitis B. Gut 2008;57(1):105–124

    Article  PubMed  CAS  Google Scholar 

  16. Robek MD, Boyd BS, Wieland SF, Chisari FV. Signal transduction pathways that inhibit hepatitis B virus replication. Proc Natl Acad Sci USA 2004;101(6):1743–1747

    Article  PubMed  CAS  Google Scholar 

  17. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, Ehrlich GK, Pan W, Xu ZX, Modi MW, Farid A, Berthold W, Graves M. Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001;12(2):195–202

    Article  PubMed  CAS  Google Scholar 

  18. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365(9454):123–129

    Article  PubMed  CAS  Google Scholar 

  19. Ank N, Paludan SR. Type III IFNs: new layers of complexity in innate antiviral immunity. Biofactors 2009;35(1):82–87

    Article  PubMed  CAS  Google Scholar 

  20. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003;4(1):69–77

    Article  PubMed  CAS  Google Scholar 

  21. Mordstein M, Neugebauer E, Ditt V, Jessen B, Rieger T, Falcone V, Sorgeloos F, Ehl S, Mayer D, Kochs G, Schwemmle M, Gunther S, Drosten C, Michiels T, Staeheli P. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol 2010;84(11):5670–5677

    Article  PubMed  CAS  Google Scholar 

  22. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003;4(1):63–68

    Article  PubMed  CAS  Google Scholar 

  23. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008;4(3):e1000017

    Article  PubMed  Google Scholar 

  24. Pagliaccetti NE, Chu EN, Bolen CR, Kleinstein SH, Robek MD. Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities. Virology 2010;401(2):197–206

    Article  PubMed  CAS  Google Scholar 

  25. Doyle CM, Han J, Weigert MG, Prak ET. Consequences of receptor editing at the lambda locus: multireactivity and light chain secretion. Proc Natl Acad Sci USA 2006;103(30):11264–11269

    Article  PubMed  CAS  Google Scholar 

  26. Hong SH, Cho O, Kim K, Shin HJ, Kotenko SV, Park S. Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res 2007;126(1–2):245–249

    Article  PubMed  CAS  Google Scholar 

  27. O’Brien TR. Interferon-alfa, interferon-lambda and hepatitis C. Nat Genet 2009;41(10):1048–1050

    Article  PubMed  Google Scholar 

  28. Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, Gordon SC, Marotta P, Vierling JM, Carlos Lopez-Talavera J, Byrnes-Blake K, Fontana D, Freeman J, Gray T, Hausman D, Hunder NN, Lawitz E. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010 (Epub ahead of print)

  29. Kakumu S, Ishikawa T, Mizokami M, Orido E, Yoshioka K, Wakita T, Yamamoto M. Treatment with human gamma interferon of chronic hepatitis B: comparative study with alpha interferon. J Med Virol 1991;35(1):32–37

    Article  PubMed  CAS  Google Scholar 

  30. Weng HL, Wang BE, Jia JD, Wu WF, Xian JZ, Mertens PR, Cai WM, Dooley S. Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study. Clin Gastroenterol Hepatol 2005;3(8):819–828

    Article  PubMed  CAS  Google Scholar 

  31. Zoulim F, Locarnini S. 2009. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137(5):1593–1608, e1591–e1592

    Google Scholar 

  32. Sung JJ, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo RP, Brosgart CL, Woessner MA, Scott SA, Gray DF, Gardner SD. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008;48(5):728–735

    Article  PubMed  CAS  Google Scholar 

  33. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352(26):2682–2695

    Article  PubMed  CAS  Google Scholar 

  34. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351(12):1206–1217

    Article  PubMed  CAS  Google Scholar 

  35. Fleischer RD, Lok AS. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol 2009;51(4):787–791

    Article  PubMed  CAS  Google Scholar 

  36. Jang JH, Kim JW, Jeong SH, Myung HJ, Kim HS, Park YS, Lee SH, Hwang JH, Kim N, Lee DH. Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy. J Viral Hepat (Epub ahead of print)

  37. Kim BK, Oh J, Kwon SY, Choe WH, Ko SY, Rhee KH, Seo TH, Lim SD, Lee CH. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol 2009;51(4):829–834

    Article  PubMed  Google Scholar 

  38. Yuen MF, Han KH, Um SH, Yoon SK, Kim HR, Kim J, Kim CR, Lai CL. Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. Hepatology 2010;51(3):767–776

    Article  PubMed  CAS  Google Scholar 

  39. Yuen MF, Kim J, Kim CR, Ngai V, Yuen JC, Min C, Kang HM, Shin BS, Yoo SD, Lai CL. A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. Antivir Ther 2006;11(8):977–983

    PubMed  CAS  Google Scholar 

  40. Yuen MF, Lee SH, Kang HM, Kim CR, Kim J, Ngai V, Lai CL. Pharmacokinetics of LB80331 and LB80317 following oral administration of LB80380, a new antiviral agent for chronic hepatitis B (CHB), in healthy adult subjects, CHB patients, and mice. Antimicrob Agents Chemother 2009;53(5):1779–1785

    Article  PubMed  CAS  Google Scholar 

  41. Erion MD, van Poelje PD, Mackenna DA, Colby TJ, Montag AC, Fujitaki JM, Linemeyer DL, Bullough DA. Liver-targeted drug delivery using HepDirect prodrugs. J Pharmacol Exp Ther 2005;312(2):554–560

    Article  PubMed  CAS  Google Scholar 

  42. Herman BD, Votruba I, Holy A, Sluis-Cremer N, Balzarini J. The acyclic 2, 4-diaminopyrimidine nucleoside phosphonate acts as a purine mimetic in HIV-1 reverse transcriptase DNA polymerization. J Biol Chem 2010;285(16):12101–12108

    Article  PubMed  CAS  Google Scholar 

  43. Brunelle MN, Lucifora J, Neyts J, Villet S, Holy A, Trepo C, Zoulim F. In vitro activity of 2, 4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. Antimicrob Agents Chemother 2007;51(6):2240–2243

    Article  PubMed  CAS  Google Scholar 

  44. Balzarini J, Pannecouque C, Naesens L, Andrei G, Snoeck R, De Clercq E, Hockova D, Holy A. 6-[2-phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines: a new class of acyclic pyrimidine nucleoside phosphonates with antiviral activity. Nucleosides Nucleotides Nucleic Acids 2004;23(8–9):1321–1327

    Article  PubMed  CAS  Google Scholar 

  45. Babinet C, Farza H, Morello D, Hadchouel M, Pourcel C. Specific expression of hepatitis B surface antigen (HBsAg) in transgenic mice. Science 1985;230(4730):1160–1163

    Article  PubMed  CAS  Google Scholar 

  46. Chisari FV, Pinkert CA, Milich DR, Filippi P, McLachlan A, Palmiter RD, Brinster RL. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science. 1985;230(4730):1157–1160

    Article  PubMed  CAS  Google Scholar 

  47. Sun D, Nassal M. Stable HepG2- and Huh7-based human hepatoma cell lines for efficient regulated expression of infectious hepatitis B virus. J Hepatol 2006;45(5):636–645

    Article  PubMed  CAS  Google Scholar 

  48. Root MJ, Steger HK. HIV-1 gp41 as a target for viral entry inhibition. Curr Pharm Des 2004;10(15):1805–1825

    Article  PubMed  CAS  Google Scholar 

  49. Gripon P, Cannie I, Urban S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol 2005;79(3):1613–1622

    Article  PubMed  CAS  Google Scholar 

  50. Petersen J, Dandri M, Mier W, Lutgehetmann M, Volz T, von Weizsacker F, Haberkorn U, Fischer L, Pollok JM, Erbes B, Seitz S, Urban S. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008;26(3):335–341

    Article  PubMed  CAS  Google Scholar 

  51. Kock J, Blum HE. Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H. J Gen Virol 2008;89(Pt 5):1184–1191

    Article  PubMed  Google Scholar 

  52. Rosler C, Kock J, Kann M, Malim MH, Blum HE, Baumert TF, von Weizsacker F. APOBEC-mediated interference with hepadnavirus production. Hepatology 2005;42(2):301–309

    Article  PubMed  Google Scholar 

  53. Vartanian JP, Henry M, Marchio A, Suspene R, Aynaud MM, Guetard D, Cervantes-Gonzalez M, Battiston C, Mazzaferro V, Pineau P, Dejean A, Wain-Hobson S. Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathog 2010;6(5):e1000928

    Article  PubMed  Google Scholar 

  54. Turelli P, Mangeat B, Jost S, Vianin S, Trono D. Inhibition of hepatitis B virus replication by APOBEC3G. Science 2004;303(5665):1829

    Article  PubMed  Google Scholar 

  55. Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N, Kubo M, Tsunoda T, Kamatani N, Kumada H, Puseenam A, Sura T, Daigo Y, Chayama K, Chantratita W, Nakamura Y, Matsuda K. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009;41(5):591–595

    Article  PubMed  CAS  Google Scholar 

  56. Lau GK, Ye D. Novel insights into the association between HLA-DP variants and persistent hepatitis B virus infection: a genome-wide association study. Gastroenterology 2010;138(1):394–396

    Article  PubMed  Google Scholar 

  57. Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G, Levrero M. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 2006;130(3):823–837

    Article  PubMed  CAS  Google Scholar 

  58. Zimmerman KA, Fischer KP, Joyce MA, Tyrrell DL. Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture. J Virol 2008;82(16):8013–8021

    Article  PubMed  CAS  Google Scholar 

  59. Durantel D, Alotte C, Zoulim F. Glucosidase inhibitors as antiviral agents for hepatitis B and C. Curr Opin Investig Drugs 2007;8(2):125–129

    PubMed  CAS  Google Scholar 

  60. Mehta A, Carrouee S, Conyers B, Jordan R, Butters T, Dwek RA, Block TM. Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications. Hepatology 2001;33(6):1488–1495

    Article  PubMed  CAS  Google Scholar 

  61. Stray SJ, Bourne CR, Punna S, Lewis WG, Finn MG, Zlotnick A. A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc Natl Acad Sci USA 2005;102(23):8138–8143

    Article  PubMed  CAS  Google Scholar 

  62. Bourne C, Lee S, Venkataiah B, Lee A, Korba B, Finn MG, Zlotnick A. Small-molecule effectors of hepatitis B virus capsid assembly give insight into virus life cycle. J Virol 2008;82(20):10262–10270

    Article  PubMed  CAS  Google Scholar 

  63. Zhu X, Zhao G, Zhou X, Xu X, Xia G, Zheng Z, Wang L, Yang X, Li S. 2,4-Diaryl-4,6,7,8-tetrahydroquinazolin-5(1H)-one derivatives as anti-HBV agents targeting at capsid assembly. Bioorg Med Chem Lett 2010;20(1):299–301

    Article  PubMed  CAS  Google Scholar 

  64. Wu GY, Zheng XJ, Yin CC, Jiang D, Zhu L, Liu Y, Wei L, Wang Y, Chen HS. Inhibition of hepatitis B virus replication by Bay 41–4109 and its association with nucleocapsid disassembly. J Chemother 2008;20(4):458–467

    PubMed  Google Scholar 

  65. Stray SJ, Zlotnick A. BAY 41–4109 has multiple effects on hepatitis B virus capsid assembly. J Mol Recognit 2006;19(6):542–548

    Article  PubMed  CAS  Google Scholar 

  66. Feld JJ, Colledge D, Sozzi V, Edwards R, Littlejohn M, Locarnini SA. The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Res 2007;76(2):168–177

    Article  PubMed  CAS  Google Scholar 

  67. Delaney WE, Edwards R, Colledge D, Shaw T, Furman P, Painter G, Locarnini S. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother. 2002;46(9):3057–3060

    Article  PubMed  CAS  Google Scholar 

  68. Tseng YP, Kuo YH, Hu CP, Jeng KS, Janmanchi D, Lin CH, Chou CK, Yeh SF. The role of helioxanthin in inhibiting human hepatitis B viral replication and gene expression by interfering with the host transcriptional machinery of viral promoters. Antiviral Res 2008;77(3):206–214

    Article  PubMed  CAS  Google Scholar 

  69. Ying C, Li Y, Leung CH, Robek MD, Cheng YC. Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. Proc Natl Acad Sci USA 2007;104(20):8526–8531

    Article  PubMed  CAS  Google Scholar 

  70. Anderson VR, Curran MP. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs 2007;67(13):1947–1967

    Article  PubMed  CAS  Google Scholar 

  71. Keeffe EB, Rossignol JF. Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides. World J Gastroenterol 2009;15(15):1805–1808

    Article  PubMed  CAS  Google Scholar 

  72. Elazar M, Liu M, McKenna SA, Liu P, Gehrig EA, Puglisi JD, Rossignol JF, Glenn JS. The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. Gastroenterology 2009;137(5):1827–1835

    Article  PubMed  CAS  Google Scholar 

  73. Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S, Ayers MS, Rossignol JF. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 2008;77(1):56–63

    Article  PubMed  CAS  Google Scholar 

  74. Rossignol JF, Keeffe EB. Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C. Future Microbiol 2008;3:539–545

    Article  PubMed  CAS  Google Scholar 

  75. Zundorf I, Dingermann T. siRNAs—your friend and helper? Pharm Unserer Zeit 2009;38(1):9–11

    Article  PubMed  Google Scholar 

  76. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009;457(7228):426–433

    Article  PubMed  CAS  Google Scholar 

  77. Sun D, Rosler C, Kidd-Ljunggren K, Nassal M. Quantitative assessment of the antiviral potencies of 21 shRNA vectors targeting conserved, including structured, hepatitis B virus sites. J Hepatol 2010;52(6):817–826

    Article  PubMed  CAS  Google Scholar 

  78. Locarnini S. Therapies for hepatitis B: where to from here? Gastroenterology 2005;128(3):789–792

    Article  PubMed  Google Scholar 

  79. Ilan Y, Nagler A, Adler R, Tur-Kaspa R, Slavin S, Shouval D. Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology 1993;104(6):1818–1821

    PubMed  CAS  Google Scholar 

  80. Lau GK, Lok AS, Liang RH, Lai CL, Chiu EK, Lau YL, Lam SK. Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology 1997;25(6):1497–1501

    Article  PubMed  CAS  Google Scholar 

  81. Loggi E, Bihl F, Chisholm JV 3rd, Biselli M, Bontadini A, Vitale G, Ercolani G, Grazi GL, Pinna AD, Bernardi M, Brander C, Andreone P. Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft. J Hepatol 2009;50(3):625–630

    Article  PubMed  Google Scholar 

  82. Bertoletti A, Gehring A. Therapeutic vaccination and novel strategies to treat chronic infection. Expert Rev Gastroenterol Hepatol 2009;3(5):561–569

    Article  PubMed  CAS  Google Scholar 

  83. Ciancio A, Rizzetto M. Thymalfasin in the treatment of hepatitis B and C. Ann NY Acad Sci 2010;1194:141–146

    Article  PubMed  CAS  Google Scholar 

  84. Zhang YY, Chen EQ, Yang J, Duan YR, Tang H. Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. Virol J 2009;6:63

    Article  PubMed  Google Scholar 

  85. Pol S, Nalpas B, Driss F, Michel ML, Tiollais P, Denis J, Brecho C. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 2001;34(6):917–921

    Article  PubMed  CAS  Google Scholar 

  86. Vandepapeliere P, Lau GK, Leroux-Roels G, Horsmans Y, Gane E, Tawandee T, Merican MI, Win KM, Trepo C, Cooksley G, Wettendorff M, Ferrari C. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 2007;25(51):8585–8597

    Article  PubMed  CAS  Google Scholar 

  87. Rahman F, Dahmen A, Herzog-Hauff S, Bocher WO, Galle PR, Lohr HF. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology 2000;31(2):521–527

    Article  PubMed  CAS  Google Scholar 

  88. Jung MC, Gruner N, Zachoval R, Schraut W, Gerlach T, Diepolder H, Schirren CA, Page M, Bailey J, Birtles E, Whitehead E, Trojan J, Zeuzem S, Pape GR. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: Induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. Vaccine 2002;20(29–30):3598–3612

    Article  PubMed  CAS  Google Scholar 

  89. Heathcote J, McHutchison J, Lee S, Tong M, Benner K, Minuk G, Wright T, Fikes J, Livingston B, Sette A, Chestnut R. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 1999;30(2):531–536

    Article  PubMed  CAS  Google Scholar 

  90. Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, LaFond R, Yuan L, Chisari FV, Furze J, Bartholomeuz R, et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 1995;95(1):341–349

    Article  PubMed  CAS  Google Scholar 

  91. Akbar SM, Murakami H, Horiike N, Onji M. Dendritic cell-based therapies in the bench and the bedsides. Curr Drug Targets Inflamm Allergy 2004;3(3):305–310

    Article  PubMed  CAS  Google Scholar 

  92. Xu DZ, Zhao K, Guo LM, Li LJ, Xie Q, Ren H, Zhang JM, Xu M, Wang HF, Huang WX, Bai XF, Niu JQ, Liu P, Chen XY, Shen XL, Yuan ZH, Wang XY, Wen YM. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS One 2008;3(7):e2565

    Article  PubMed  Google Scholar 

  93. Yao X, Zheng B, Zhou J, Xu DZ, Zhao K, Sun SH, Yuan ZH, Wen YM. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine 2007;25(10):1771–1779

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Medicine II, University of Freiburg, Freiburg, Germany

    Daniel Grimm, Robert Thimme & Hubert E. Blum

Authors
  1. Daniel Grimm
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Thimme
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hubert E. Blum
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hubert E. Blum.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grimm, D., Thimme, R. & Blum, H.E. HBV life cycle and novel drug targets. Hepatol Int 5, 644–653 (2011). https://doi.org/10.1007/s12072-011-9261-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-011-9261-3

Keyword

Search

Navigation